5 Key Takeaways

• 1

  Oral gildeuretinol acetate did not significantly slow geographic atrophy progression compared to placebo in age-related macular degeneration patients.

• 2

  The phase 2/3 SAGA trial involved 198 patients aged 60 and older, assigned to receive either gildeuretinol or placebo for 24 months.

• 3

  Geographic atrophy lesion growth was reduced by 13% with gildeuretinol, but this difference was not statistically significant.

• 4

  Secondary outcomes showed exploratory benefits for gildeuretinol, including less decline in low-luminance visual acuity and improved quality of life.

• 5

  The study's primary endpoint was not met, and researchers emphasized that secondary findings are exploratory and require further investigation.